Detalles de la búsqueda
1.
Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer.
Int J Gynecol Cancer
; 32(4): 560-565, 2022 04 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34551895
2.
Nonclinical Development of SRK-181: An Anti-Latent TGFß1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors.
Int J Toxicol
; 40(3): 226-241, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33739172
3.
Excisional treatment comparison for in situ endocervical adenocarcinoma (EXCISE): A phase 2 pilot randomized controlled trial to compare histopathological margin status, specimen size and fragmentation after loop electrosurgical excision procedure and cold knife cone biopsy.
Gynecol Oncol
; 159(3): 623-629, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33032824
4.
A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases.
Mod Pathol
; 32(12): 1834-1846, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31239549
5.
New Insights in Tissue Distribution, Metabolism, and Excretion of [3H]-Labeled Antibody Maytansinoid Conjugates in Female Tumor-Bearing Nude Rats.
Drug Metab Dispos
; 44(7): 897-910, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27122302
6.
A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events.
Br J Haematol
; 167(3): 366-75, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25139740
7.
Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors.
Invest New Drugs
; 32(1): 135-44, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23589214
8.
Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ Study.
Neurology
; 102(5): e209151, 2024 Mar 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38330285
9.
Spatial transcriptomics reveals discrete tumour microenvironments and autocrine loops within ovarian cancer subclones.
Nat Commun
; 15(1): 2860, 2024 Apr 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38570491
10.
Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing.
J Clin Invest
; 134(9)2024 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38502193
11.
Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies.
Proc Natl Acad Sci U S A
; 107(35): 15473-8, 2010 Aug 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-20713706
12.
A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma.
Br J Haematol
; 159(1): 58-66, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22861192
13.
Transcriptomic analysis of patient plasma reveals circulating miR200c as a potential biomarker for high-grade serous ovarian cancer.
Gynecol Oncol Rep
; 39: 100894, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-35005155
14.
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.
Virchows Arch
; 480(4): 855-871, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-34782936
15.
TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.
J Clin Oncol
; 40(18): 2036-2047, 2022 06 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-35263119
16.
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy.
Adv Ther
; 38(6): 3203-3222, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33963971
17.
Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study.
BMC Clin Pharmacol
; 8: 2, 2008 Mar 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-18377658
18.
Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach.
J Clin Pharmacol
; 57 Suppl 10: S105-S115, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28921642
19.
Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal Cancers.
Cancer Discov
; 7(9): 1030-1045, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28526733
20.
Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor.
Cancer Chemother Pharmacol
; 75(5): 887-95, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25721064